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Abstract 1	
 2	
The adaptive cellular response to low oxygen tensions is mediated by the hypoxia 3	
inducible factors (HIFs), a family of heterodimeric transcription factors comprised of 4	
HIFα and β subunits.  Prolonged HIF expression is a key contributor to cellular 5	
transformation, tumourigenesis and metastasis and as such HIF degradation under 6	
hypoxic conditions is an essential homeostatic and tumour suppressive mechanism. 7	
LIMD1 complexes with PHD2 and VHL in physiological oxygen (normoxia) to 8	
facilitate degradation of the HIFα subunit. Here we identify LIMD1 as a HIF-1-9	
responsive gene, which mediates a previously uncharacterised negative regulatory 10	
feedback mechanism for HIFα degradation in hypoxia, through modulation of PHD2-11	
LIMD1-VHL complex formation. Hypoxic induction of LIMD1 expression results in 12	
increased HIFα protein degradation, inhibiting HIF-1 target-gene expression, tumour 13	
growth and vascularisation. Furthermore, we report that copy number analysis of the 14	
LIMD1 locus, which has a 47.1% occurrence in lung adenocarcinoma, correlates 15	
with enhanced expression of a HIF target gene signature and is a negative 16	
prognostic indicator. Taken together, our data opens a new field of research into the 17	
aetiology, diagnosis and prognosis of LIMD1 negative lung cancers.18	
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 1	
Introduction 2	
The HIF family of transcription factors are heterodimeric proteins formed of a 3	
HIF-α and HIF-β subunit (1). HIF-α is regulated by intracellular oxygen levels; under 4	
physiological oxygen (normoxia), two highly conserved proline residues within the 5	
oxygen dependent degradation domain of the HIFα subunit (P402/564 on HIF-1α; 6	
P405/531 on HIF-2α) are hydroxylated by prolyl hydroxylase domain (PHD) proteins. 7	
Hydroxylated HIFα is then recognised and ubiquitinated by the von HippelÐLindau 8	
(VHL) E3 ubiquitin ligase complex, resulting in its degradation by the 26S 9	
proteasome (2-5). Under low oxygen (hypoxic) conditions, the hydroxylase activity of 10	
the PHD enzymes is severely inhibited; HIF therefore escapes hydroxylation and 11	
degradation to initiate a transcriptional program of cellular response and adaptation 12	
to hypoxia.  13	
Under conditions of chronic hypoxia, a negative regulatory feedback loop is 14	
initiated whereby cells become desensitised to HIFs by over-activation of PHDs, 15	
causing HIFα to be degraded(6). Neoplastic cells survive under conditions of chronic 16	
tumour hypoxia, however, due to inhibition of mechanisms that degrade HIF (7). This 17	
is exemplified by mutation of VHL mutations in clear cell renal carcinomas, leading to 18	
sustained HIFα expression and activity (8). In non-small cell lung cancer (NSCLC), 19	
deregulation of the HIF negative feedback loop is far less characterised, despite the 20	
fact that HIFα expression has been implicated as a poor prognostic indicator (9, 10). 21	
The lung tumour suppressor protein LIMD1 is a member of the Zyxin family of 22	
adaptor proteins, initially characterised as signal transducers (11) shuttling between 23	
the cytoplasm and nucleus. LIMD1 loss has been identified in lung, breast, head and 24	
neck squamous cell carcinomas and adult acute leukaemia (12-16) and its 25	
decreased expression in diffuse large B-cell lymphoma has clinical significance to 26	
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patient prognosis and disease classification/stratification (17). LIMD1 knockout mice 1	
have increased lung tumour numbers and volume and decreased survival rate 2	
compared to LIMD1 expressing control mice when either challenged with a chemical 3	
carcinogen or cross bred with KrasG12D mice(13) validating its critical role in normal 4	
cellular homeostasis. It has also been reported that silencing of LIMD1 in multidrug 5	
resistant colorectal carcinoma cells increased their chemosensitivity in vitro (18).  6	
LIMD1 is a scaffold protein that exerts multiple tumour suppressive functions 7	
depending upon on its binding partners. Basal LIMD1 gene expression is under the 8	
control of PU.1, a member of the Ets family of transcription factors(19). LIMD1 9	
represses cell cycle progression through pRb-dependent and -independent inhibition 10	
of E2F (12) and regulates Hippo signalling by binding to LATS, causing 11	
sequestration of the Hippo kinase complex (20-22). LIMD1 is also part of the 12	
Slug/Snail complex that regulates E-cadherin transcription (23, 24) in addition to 13	
facilitating centrosomal localisation of BRCA2 to preventing aberrant cellular 14	
proliferation (25). LIMD1 and closely related Zyxin family members Ajuba and WTIP 15	
are also critical effectors of microRNA (miRNA) mediated gene silencing, a process 16	
generally considered to be a global tumour suppressive mechanism (26).  17	
LIMD1 forms complexes with PHD2 and VHL to post-translationally repress 18	
HIF-1α protein levels and therefore HIF-1α-mediated gene activation (2, 27). 19	
However, the physiological or clinical link between this mechanistic role of LIMD1 20	
within the PHD-LIMD1-VHL HIF regulatory complex and disease pathophysiology 21	
are unexplored. Here we reveal LIMD1 expression is up-regulated in hypoxia, 22	
through a functional HIF-1α specific hypoxic response element (HRE) within the CpG 23	
Island in its promoter. LIMD1 facilitates HIF-1α protein degradation under hypoxic 24	
conditions by maintaining the PHD2/VHL/HIF-1α degradation complex, thereby 25	
reducing HIF-1α-driven gene activation. Utilising an RNAi-mediated knockdown-26	
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rescue system, we have identified that inhibition of hypoxia-driven LIMD1 expression 1	
causes HIF-1α protein stabilisation and HIF target-gene activation. In vivo, inhibition 2	
of hypoxia-driven LIMD1 expression results in larger and more vascularised 3	
xenograft tumours. Finally, our data provides a molecular mechanistic reasoning for 4	
clinico-pathological data indicating that LIMD1 loss or haplo-insufficiency correlated 5	
with elevated HIF-1α-driven gene expression within lung tumours is associated with 6	
poorer patient prognosis and survival. 7	
 8	
Results 9	
LIMD1 is a HIF-1-responsive gene 10	
Homeostatic signalling pathways often have in-built self-regulatory feedback 11	
mechanisms to attenuate their activation(28). With this in mind, we considered our 12	
initial discovery of LIMD1 acting to scaffold the PHDs and VHL, and hypothesised 13	
that LIMD1 itself might be a HIF target gene. We therefore assessed endogenous 14	
LIMD1 expression in a panel of cell lines exposed to 1% O2 (henceforth referred to 15	
as hypoxia), including transformed cancer lines (A549, HeLa, HEK293 and U2OS), 16	
non-transformed small airway epithelial cells (SAEC) and primary human dermal 17	
fibroblasts (hDF), and observed an increase in LIMD1 mRNA and protein expression 18	
compared to the normoxic LIMD1 expression level for each cell line (Fig. 1A-C and 19	
Fig. S1A-B). The previously characterised hypoxic responsive gene PHD2 was also 20	
assayed as positive control (Fig. 1B and Fig. S1C, E). In contrast PHD1 is not a 21	
hypoxia responsive gene (29)  and its expression was unaffected in hypoxic 22	
conditions (Fig. S1D). It is of note that LIMD1 is induced in hypoxia following the 23	
maximal stabilisation of either HIF-1 or 2α (Fig. 1B and Fig. S1A), implying that 24	
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hypoxia/HIF may be cascading either epigenetic or further unknown mechanisms of 1	
gene transactivation.  2	
In silico analysis of the LIMD1 promoter identified three putative hypoxic 3	
response elements (HRE 1-3) (Fig. S1H (19)). To assess their functionality, we used 4	
a LIMD1 promoter-driven luciferase reporter construct, spanning 1990bp upstream 5	
from the LIMD1 transcriptional start site (as predicted by the RefSeq NM_014240.2) 6	
and encompassing all three predicted HRE elements. Within this construct we 7	
created a series of ten consecutive small internal deletions within the CpG Island 8	
that have previously been identified as containing transcriptional regulatory 9	
elements(19) (Fig. S1I). These reporter constructs displayed ~3-fold induction of wild 10	
type LIMD1 promoter activity in hypoxia compared to normoxia. However, deletion of 11	
the 31bp Δ3 region that encompasses the predicted HRE3 ablated any hypoxic 12	
increase (Fig. S1J). Furthermore, generation of internal deletion mutants at the 13	
precise predicted HRE loci confirmed HRE3 to be the active hypoxia responsive 14	
element within the LIMD1 promoter (Fig. 1D-E). The position and sequence of this 15	
HRE is also highly conserved, further supporting its functional importance (Fig. 1F-16	
G).  17	
We next determined which HIFα paralogue was involved in LIMD1 regulation 18	
by combining the LIMD1 promoter luciferase reporters(19) with shRNA-mediated 19	
knockdown of HIF-1α and HIF-2α. Depletion of HIF-1α, but not HIF-2α, prevented 20	
induction of LIMD1 expression in hypoxia (Fig. S2A). This finding was corroborated 21	
by ChIP and EMSA analyses, which demonstrated HIF-1 binding to the LIMD1 22	
promoter (Fig. 2A, B). siRNA mediated depletion of HIF-1α reduced LIMD1 protein 23	
and mRNA expression under hypoxic, and to a lesser extent, normoxic conditions in 24	
all cell lines examined, including SAEC (Fig. 2C-D and Fig. S2B-D). LIMD1 25	
depletion did not affect HIF-1 or 2α mRNA expression (Fig. S2E-H). The decrease in 26	
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normoxic LIMD1 expression following si-HIF-1α demonstrates that basal normoxic 1	
HIF-1 activity is required for LIMD1 expression; an observation that has been 2	
previously described for other genes (30), and that under hypoxia, HIF preferentially 3	
binds to gene loci that are already transcriptionally active to further activate their 4	
hypoxic gene expressions (31). Thus these data show that under hypoxia, HIF-1 5	
binds the LIMD1 promoter and increases LIMD1 expression.  6	
Under normoxic conditions, LIMD1 scaffolds PHD2 and VHL to enable 7	
efficient degradation of HIF-1α (2). Given that LIMD1 is a hypoxia responsive gene, 8	
we next performed endogenous co-immunoprecipitation assays to assess whether 9	
the PHD2-LIMD1-VHL complex also exists under low oxygen tensions. Indeed, 10	
under hypoxia, LIMD1 co-precipitated with PHD2 and VHL (Fig. 2E and Fig. S2I); 11	
HIF-1α and HIF-2α also co-precipitated with LIMD1, which may be due to the 12	
increased protein stability of the HIF proteins under this low oxygen tension. These 13	
data demonstrate active engagement of the PHD-LIMD1-VHL complex with their HIF 14	
target protein in hypoxia. However, HIF-1β did not co-precipitate within this complex, 15	
indicating independent of oxygen tensions, LIMD1 was facilitating HIFα degradation 16	
prior to hetero-dimerisation with the HIFβ subunit. Thus in hypoxia, LIMD1 17	
expression facilitates formation of an active PHD2-LIMD1-VHL HIF-degradation 18	
complex.  19	
 20	
HIF-1-driven LIMD1 expression is required for negative regulation of HIF in a hypoxic 21	
environment 22	
LIMD1 protein expression has been previously shown to be significantly reduced or 23	
lost in human lung and breast cancers (12-14). This led us to hypothesise that a 24	
decrease in LIMD1 protein expression as a result of LIMD1 loss of heterozygosity 25	
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(LOH) or promoter methylation (13) may cause disruption of the hypoxic PHD-1	
LIMD1-VHL complex, and exacerbate HIF-mediated gene expression and pro-2	
transforming effects in the context of a hypoxic tumour microenvironment.  3	
In order to directly assay the effects of hypoxia-driven LIMD1 expression, we 4	
utilised a lentiviral shRNA-mediated knockdown-rescue system that concurrently 5	
expresses a shRNA and a cDNA (2) (Fig. 3A schematic). We utilised this system to 6	
express a shLIMD1 to deplete cells of endogenous LIMD1, whilst simultaneously re-7	
expressing an RNAi resistant (rr) Flag epitope tagged LIMD1 that was under the 8	
control of the endogenous LIMD1 promoter (corresponding to nucleotides 45634323-9	
6323 on the primary chromosome 3 ref assembly NC_000003.11, described in(19) 10	
and which has previously been identified as being an active and regulated promoter 11	
sequence). The promoter sequence contained the wild-type HRE (HREwt); we then 12	
mutated this HRE sequence (HREmut) (Fig. S3A). Ectopic LIMD1 expression in cells 13	
transduced with these vectors (where endogenous LIMD1 is removed by the 14	
shRNA), would therefore be either enhanced (HREwt) or unchanged (HREmut) by 15	
hypoxia. We transduced U2OS, HeLa and SAEC with the paired set of lentiviruses 16	
described, and determined LIMD1 controlled by the HREwt promoter had a 2-3 fold 17	
increase in LIMD1 protein expression in hypoxia in the experimental context of this 18	
pooled (non-clonal) heterogeneous population. In contrast, mutation of the HRE 19	
within the LIMD1 promoter (HREmut) significantly impaired hypoxic induction of 20	
LIMD1 in these lines (Fig. 3B-E and Fig. S3B-E). This was coupled with an 21	
impairment of the temporal adaptive regulation of HIF-1α under increasing exposure 22	
to hypoxia. Reduction in HIF-1α levels observed in the HREwt lines after 24 hours 23	
hypoxic exposure was comparable to that observed after 48 hours hypoxic exposure 24	
in the HREmut lines (Fig. 3F-H). Of note, the HREmut cells had increased expression 25	
of HIF-1α mRNA after 24 hours in hypoxia compared to the HREwt, cells (Fig. S3F), 26	
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which we postulate may be the result of increased HIF-1α protein in this line further 1	
driving its own transcription (32). The HREmut cells also exhibited increased HIF-2	
driven luciferase activity (Fig. 3I and Fig. S3G), endogenous HIF-1-driven gene 3	
activation (Fig. 3J and Fig. S3H-K) and cumulative secreted VEGF-A through 48 4	
hours hypoxia (Fig. 3K and Fig. S3L) when compared to the HREwt cells.  5	
We then wished to ascertain whether the differences observed in the HIF-1-6	
driven geno/phenotypes (Fig. 3) were both HIF specific and due to the effects that 7	
LIMD1 expression was exerting on HIF-1α protein turnover. Treatment with the 8	
translational inhibitor cycloheximide (Cx) to assess the degradation rate of HIF 9	
revealed the HREmut line had a significantly decreased rate of both HIF-1α and HIF-10	
2α turnover compared to the HREwt line (Fig. 4A-B). Furthermore, siRNA depletion 11	
of HIF-1α ablated the differential gene expression of VEGF-A between the lines (Fig. 12	
4C- D). Of note, depletion of HIF-2α also decreased VEGF-A expression, which is 13	
likely due to VEGF-A being a dual HIF-1 and HIF-2 target gene (33). The differences 14	
in HIF mediated genotypes observed between the HREwt and HREmut cell lines (Fig. 15	
3E-G) was therefore a result of increased HIF-1α protein turnover caused by 16	
enhanced LIMD1 expression, and not due to any HIF independent mechanisms.  17	
To exclude the possibility that the miRNA-silencing function of LIMD1(26) was 18	
complicit in this observation, we utilised luciferase reporter constructs containing the 19	
HIF-1/2α 3ÕUTRs (as defined from RefSeq identifiers NM_001530.3 and 20	
NM_001430.4 respectively). We did not observe any differences in HIFα 3Õ UTR 21	
regulation in LIMD1 expressing or null cells regardless of oxygen tension (Fig. 4E), 22	
indicating that LIMD1 was only affecting HIFα levels post-translationally and not 23	
post-transcriptionally in this experimental context of subtle but significance change in 24	
LIMD1 protein induction (2-3 fold increase (Fig. 3A)). Together, these data reveal 25	
that inhibition of the LIMD1 feedback loop causes an increased cellular hypoxic HIF 26	
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phenotype in vitro, demonstrating increased hypoxic LIMD1 protein expression is 1	
necessary for correct modulation of HIF-1 expression and signalling in a hypoxic 2	
environment. 3	
 4	
Ablation of HIF-driven LIMD1 expression promotes tumour growth 5	
We next investigated the physiological relevance of this newly identified hypoxic HIF-6	
1-LIMD1 negative feedback loop using in vivo xenograft tumour growth as a model 7	
system. LIMD1 is a lung tumour suppressor, with decreased mRNA and protein 8	
expression shown to occur in a large proportion of lung adenocarcinomas (13). For 9	
our xenograft model we therefore utilised the A549 lung adenocarcinoma cell line. 10	
A549 LIMD1 HREwt and HREmut cell lines were created as described above. The 11	
transduced cell lines were validated in vitro, where ablation of the hypoxic induction 12	
in LIMD1 expression in the HREmut line increased synthetic HIF-1-driven luciferase 13	
activity, HIF-1-responsive genes and secreted VEGF (Fig. 5A-C). These findings 14	
also corroborated with the results obtained in U2OS and HeLa cells (Fig. 3 and Fig. 15	
S3).  16	
Sub-cutaneous xenografts were established on the flanks of SCID/Beige mice 17	
from either the A549 LIMD1 HREwt or HREmut cell lines. Xenografts from A549 18	
HREmut cells (which have an impaired HIF-LIMD1 negative feedback loop) had 19	
increased age matched endpoint tumour volumes compared to A459 HREwt cells 20	
(which have an in-tact HIF-LIMD1 negative feedback loop) (Fig. 5D). The effect on in 21	
vivo tumour growth was not due to intrinsic differences in proliferation rates as HREwt 22	
and HREmut cells had similar growth rates in in vitro proliferation assays or in 23	
clonogenic colony formation assays under either normoxia or hypoxia (Fig. S4A-B). 24	
Endomucin staining, as a marker of blood vessels, revealed increased vasculature in 25	
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HREmut A549-derived xenografts (Fig. 5E-F), and was corroborated with increased 1	
endomucin mRNA expression (Fig. 5G) along with an increased HIF-1-mediated 2	
gene expression profile of pro-angiogenic and glycolytic genes (Fig. 5H-J and Fig. 3	
S4C-O). HIF-1α mRNA expression was not altered upon LIMD1 loss (Fig. S3F), 4	
demonstrating that the increase in HIF-1-driven gene expression was not due to 5	
increased HIF-1α transcription. Together these data identify that ablation of this HIF-6	
1-LIMD1 negative regulatory feedback mechanism in vivo increases tumour growth 7	
and vascularisation. 8	
 9	
LIMD1 is a prognostic indicator in NSCLC 10	
Finally, to investigate the clinical relevance and significance of our in vitro and in vivo 11	
findings in NSCLC, we examined LIMD1 protein expression in a tissue microarray of 12	
276 lung cancer patients and investigated correlation with patient outcome 13	
(Representative staining Fig. 6A; Marker distribution Fig. 6B). In agreement with 14	
previous studies, LIMD1 protein expression was detected in both nuclear and 15	
cytoplasmic compartments (13, 34). Kaplan-Meier survival analysis demonstrated 16	
patients exhibiting low LIMD1 expression within this cohort had significantly worse 17	
overall survival compared to those with high LIMD1 expression (p=0.045) (Fig. 6C). 18	
Immunohistochemical analysis of HIF-1α and downstream angiogenic marker VEGF-19	
A was not significantly correlated with LIMD1 expression in this cohort, however high 20	
VEGF expression was correlated with poor patient prognosis (p=0.045) (Fig. S5, Fig 21	
S6A-C).  22	
We next interrogated The Cancer Genome Atlas (TCGA) data sets to assess 23	
LIMD1 loss in a much larger cohort of NSCLC. First, gene copy number analysis of 24	
LIMD1 and a number of other well characterised tumour suppressor genes in lung 25	
Foxler et al. 2018 
13	|	P a g e 	
	
adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC) cohorts (n=516 and 1	
n=501, respectively) demonstrated that single (shallow) or bi-allele (16) deletion of 2	
the LIMD1 gene occurred in 47.1% (LUAD) and 85.4% of patients (LUSC) (Fig. 6D 3	
and Fig. S6D). Regression analysis demonstrated correlation between LIMD1 copy 4	
number and reduced mRNA expression (Fig. S6E-F), therefore lung 5	
adenocarcinoma patients were stratified into risk groups (quartiles) based on mRNA 6	
abundance intensities, and patient survival was determined using a Cox proportional 7	
hazards model. We determined that patients in the risk group exhibiting high LIMD1 8	
expression (High Exp) had increased overall survival, whereas patients exhibiting 9	
low LIMD1 expression (Low Exp) had reduced overall survival (log rank P = 0.021, 10	
HR 0.6) (Fig. 6E).  11	
In order to assess the impact of LIMD1 loss upon HIF regulation and outcome 12	
in these patients, we analysed the TCGA LUAD cohort to identify hypoxia/HIF 13	
signature genes correlated with low LIMD1 expression. We identified a strong 14	
inverse correlation between LIMD1 and HIF target genes SLC2A1, GAPDH and 15	
IGF2BP2 mRNA expression (Fig. 6F-H). Kaplan-Meier analysis of survival of 16	
patients stratified by expression of these genes revealed that patients with the 17	
highest expression of these genes have significantly worse overall survival 18	
compared to patients who demonstrate the lowest expression (Fig. 6I-K).  19	
To complement the bioinformatic analysis of patient tumours, we performed 20	
cell line based in vitro analysis of the gene expression changes that occur in a 21	
primary lung epithelial cell background following a reduction in LIMD1 expression. 22	
We therefore used siRNA to knockdown LIMD1 from primary human bronchial 23	
epithelial cells (HBECs) and performed micro-array analysis to identify the resultant 24	
gene ontology changes. Due to the cell type used in this analysis, this models the 25	
role of LIMD1 loss in lung SCC. Differentially expressed genes and associated 26	
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pathways following depletion of LIMD1 were analysed by Ingenuity Pathway Analysis 1	
(IPA), and this identified up-regulation of HIF-1α and a network of HIF-1 interactions 2	
following LIMD1 loss (Fig. S7, Fig. S8 and Table S1). 3	
 4	
In summary, these findings reveal the existence of a previously uncharacterised 5	
tumour suppressive negative regulatory feedback loop facilitating HIF degradation in 6	
hypoxia (Fig. 7). These findings add another level to the rapidly growing number of 7	
pathways and processes that regulate HIF. This is the first example of the main 8	
scaffold protein LIMD1 within the regulatory PHD2-LIMD1-VHL complex being itself 9	
regulated by HIF and therefore providing this regulatory triad with an intrinsic 10	
homeostatic negative regulatory functionality, which when deregulated contributes to 11	
lung adenocarcinoma tumour growth. 12	
 13	
Discussion 14	
In this study, we have demonstrated that LIMD1 expression is induced in hypoxia, 15	
where through simultaneous binding to VHL and PHD2, it facilitates degradation of 16	
HIF-1α under hypoxic conditions. Compared to the acute hypoxic responsiveness of 17	
PHD2 to HIF-1/hypoxia, hypoxia-driven LIMD1 expression occurs after prolonged 18	
exposure to hypoxia (24 hours). HIF-1-driven LIMD1 expression enables the cell to 19	
degrade HIF-1α under conditions of chronic hypoxia to prevent prolonged HIF-1 20	
activation, frequently associated with an oncogenic phenotype. In a xenograft model 21	
for tumourigenesis, ablation of the hypoxic increase in LIMD1 expression and 22	
subsequent loss of hypoxic HIF-1α protein regulation caused increased tumour 23	
vasculature and growth. From a clinical perspective, decreased LIMD1 expression 24	
correlates with increased expression of HIF target genes SLC2A1, GAPDH and 25	
IGF2BP2, which each represent significantly worse survival outcomes for patients.  26	
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By virtue of its scaffold function, the cellular processes and pathways that 1	
LIMD1 (and the Ajuba-subfamily of LIM-domain containing proteins) regulates are 2	
dependent on its protein partners. HIFα is post-transcriptionally regulated(35), 3	
including by microRNA	 -20b, -199a and -424(36-38). To therefore rule out the 4	
possibility that the miRNA-silencing function of LIMD1(26) was contributing to the 5	
observations made, we identified that loss of LIMD1 does not affect the stability or 6	
silencing of HIF-1/2α mRNA. LIMD1Õs multiple tumour suppressive functions and its 7	
discrimination between binding partners is likely to be regulated by different 8	
signalling cascades, with multiple phosphorylation events on LIMD1 having already 9	
been identified (39, 40). However, any post-translational modification events that 10	
promote LIMD1 to function preferentially in HIF regulation are yet to be elucidated, 11	
but may stem from a hypoxia/HIF activated signalling cascade (41-43). 12	
LIMD1 has few reported coding sequence mutations, and none that correlate 13	
with loss of function (44, 45). Such data suggests that gene dosage and thus small 14	
but significant changes in protein levels may be important in disease aetiology. Loss 15	
of total gene expression is frequently observed, where reduced LIMD1 gene copy 16	
number and mRNA expression occurs in a significant proportion of lung carcinomas 17	
(13). In this study, we have identified that a reduction in LIMD1 expression (through 18	
ablation of the hypoxic responsiveness of LIMD1 promoter) is sufficient to cause a 19	
HIF-mediated pathological transcriptome and phenotype in the form of tumour size 20	
and vasculature.   21	
The regulation of HIF under normoxic conditions is well characterised(4, 5), 22	
however the mechanism of HIF degradation under O2-limiting conditions is still 23	
poorly defined at the molecular level, even less so with respect to the physiological 24	
relevance, however this study begins to address this gap in our knowledge.  25	
Biological pathways often have in-built negative-feedback-loops whereby a 26	
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transcription factor induces the expression of an upstream negative regulator(28); 1	
such a negative-feedback-loop exists for the HIF proteins and the hypoxic 2	
response(29, 46-48). PHD2 depletion under hypoxia results in stabilisation of HIF-3	
1α(29), demonstrating HIFs are actively degraded and regulated regardless of 4	
oxygen tensions. Indeed the complexity of HIF regulation via the hydroxylation-5	
ubiquitination degradation pathway is becoming increasingly clear, with the 6	
identification of a plethora of HIF regulators, more recently including Siah2, SHARP1 7	
and RHOBTB3(27, 48, 49).  8	
Expression of HIFα mRNA has historically been described as constitutive, 9	
however a growing number of studies are demonstrating the existence of factors that 10	
regulate HIFα mRNA (50-52). From our investigations, the LIMD1 HREmut-derived 11	
xenografts had an increase in HIF-2α mRNA expression compared to the HREwt 12	
controls. We may postulate that inhibition of hypoxia-driven LIMD1 expression, 13	
resulting in enhanced HIFα protein stability, drives HIF-2α mRNA expression; 14	
stabilisation of HIFα protein and hypoxia have previously been described as inducers 15	
of HIF-2α mRNA expression (50, 53). 16	
Many HIF activated genes have been identified as prognostic and diagnostic 17	
markers. The oncogenic properties of HIF in cancer and disease has resulted in an 18	
abundance of potential therapeutics in development and clinical trials that target HIF 19	
at the transcriptional, translational, post-translational and functional level (54, 55). 20	
Indeed, the hypoxic HIF signalling pathway is already a therapeutic target with 21	
multiple drugs currently in clinical trials (55-57). VEGF expression is a poor 22	
prognostic indicator in NSCLC(58); as such, VEGF targeted therapies are widely 23	
used to target VEGF-mediated angiogenesis, although the details of how they exert 24	
their effects are not yet clearly defined(59). In some cases, vasculature promotion 25	
and normalisation has been demonstrated to yield greater therapeutic efficacy (60, 26	
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61). In our small cohort of 276 NSCLC, high VEGF expression was correlated with 1	
poor survival, with 80% of the cohort demonstrating high VEGF expression.  2	
Analysis of a TCGA lung adenocarcinoma cohort determined an inverse correlation 3	
between expression of LIMD1 and HIF target genes SLC2A1, GAPDH and 4	
IGF2BP2. Overexpression of glucose transporter 1 (GLUT-1), the uniporter protein 5	
encoded by the SLC2A1 gene, is correlated with poor survival in most solid tumours 6	
(62), and selective GLUT-1 inhibition has been demonstrated to inhibit glucose 7	
uptake and reduce viability of lung adenocarcinoma and squamous cell carcinoma 8	
cell lines in vitro and in vivo (63). Correlative studies have also determined 9	
upregulation or de novo expression of the IGF2BP family of oncofetal proteins 10	
across a number of solid tumours to be associated with tumour aggressiveness, 11	
metastasis and poorer overall survival (64). GAPDH overexpression is also 12	
associated with reduced patient survival (65), and therapeutic targeting of GAPDH 13	
has been demonstrated to have clinical application in both hepatocellular and 14	
colorectal cancers (66, 67). Our data correlates LIMD1 loss with overexpression of 15	
each of these HIF target genes, and as such holds potential for both stratification of 16	
patients based on a LIMD1low, SLC2A1high/IGF2BP2high/GAPDHhigh genetic profile, 17	
and targeted therapies based upon this HIF target gene signature. 18	
Taken together, our findings hold significant impact in the aetiology of LIMD1 19	
negative lung cancers, and hold the potential for advances in the diagnosis and 20	
prognosis of such cancers with respect to deregulated HIF regulation and associated 21	
oncogenic phenotypes, and subsequently hypoxia-targeted therapies.   22	
23	
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 1	
Figure Legends 2	
Figure 1: LIMD1 expression is regulated by hypoxia. The indicated panel of cell 3	
lines were exposed to either normoxia (20% O2) or hypoxia (1% O2) for up to 48 4	
hours prior to RNA and protein extraction. (A) LIMD1 mRNA and (B) protein levels 5	
were increased following hypoxic exposure. (C) Densitometric analysis of (B). (D) 6	
The LIMD1 promoter contains a hypoxic response element responsible for HIF-7	
binding and transcriptional activation of LIMD1. Three predicted HRE elements were 8	
individually deleted within the context of the wild type LIMD1 promoter-Renilla 9	
luciferase. (E) Reporter constructs in (D) were expressed in U2OS cells and exposed 10	
to hypoxia for the indicated time points. Luciferase activity was then assayed and 11	
normalised to Firefly control. Data are displayed normalised to the normoxic value for 12	
each construct.  Deletion of the third HRE present within the LIMD1 promoter 13	
(ΔHRE3) inhibited hypoxic induction of LIMD1 transcription.  (F) Sequence alignment 14	
and (G) sequence logo of LIMD1 promoters from the indicated species demonstrate 15	
that the HRE3 consensus sequence is highly conserved. Unless otherwise stated, 16	
data shown is mean ±SEM, n=3, *p<0.05, **p<0.01, ***p<0.001, n.s. = not 17	
significant, according to the studentÕs t-test.  18	
Figure 2: LIMD1 is a HIF-1 responsive gene. (A) HIF-1 binds to the LIMD1 19	
promoter. Chromatin immunoprecipitation assay (ChIP) of endogenous HIF-1α from 20	
paraformaldehyde crosslinked U2OS cells exposed to 16 hours hypoxia, followed by 21	
qRT-PCR analysis of the indicated gene promoters. (B) EMSA analysis of nuclear 22	
extracts from U2OS cells exposed to 16 hours hypoxia identified that HIF-1α but not 23	
HIF-2α bound the LIMD1 HRE consensus sequence, causing a band supershift (ss). 24	
Wild type unlabelled oligo probes that encompass the LIMD1 or PHD2 HRE were 25	
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used as controls to compete out the ss, and probes where the HRE sequences have 1	
been mutated (mLIMD1/mPHD2) were used to show specificity for HRE binding. (C) 2	
siRNA-mediated depletion of HIF-1α but not HIF-2α reduces LIMD1 expression in 3	
both normoxia and hypoxia. qRT-PCR analysis of LIMD1 mRNA from U2OS cells 4	
transfected with the indicated siRNA and maintained in normoxia or exposed to 5	
hypoxia for the indicated times. (D) Western blot analysis of protein from (C). (E) 6	
LIMD1 endogenously complexes with PHD2, VHL, HIF-1α and HIF-2α. Endogenous 7	
LIMD1 was immunoprecipitated from HeLa cells in either normoxia or following 24 8	
hours hypoxia and co-immunoprecipitated proteins identified by immunoblot 9	
analysis. Unless otherwise stated, data shown is mean ±SEM, n=3, *p<0.05, 10	
**p<0.01, ***p<0.001, n.s. = not significant, according to the studentÕs t-test. 11	
 12	
Figure 3: Induction of LIMD1 in hypoxia inhibits HIF-1-mediated gene 13	
expression. (A) A combinatorial RNAi- cDNA re-expression lentiviral cassette was 14	
utilised to create isogenic cell lines where LIMD1 was either responsive or un-15	
responsive to hypoxia. Endogenous LIMD1 was depleted by shRNA, whilst 16	
concurrently a Flag-LIMD1 cDNA was expressed that was driven by the sequence of 17	
its own endogenous promoter. (B) U2OS, HeLa and SAEC were transduced with 18	
these lentiviral cassettes to create the HREwt and HREmut paired cell lines. (C-E) 19	
Western blot quantification of LIMD1 relative to β-Actin and normalised to 0 hour 20	
time-point for each cell line. (F-H) Western blot quantification of HIF-1α relative to β-21	
Actin and normalised to 4 hour time-point for each cell line. (I) Hypoxic LIMD1 22	
induction decreases HRE-luciferase activity in hypoxia. U2OS isogenic cell lines 23	
were co-transfected with a synthetic HRE-luciferase (pNL-HRE) and pGL3 Firefly 24	
normalisation plasmid, prior to exposure to hypoxia.  Luciferase activity was assayed 25	
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and normalised against HRE activity in the HREwt line. After 24 hour hypoxic 1	
exposure the HREmut line had significantly increased luciferase activity compared to 2	
the HREwt line. (J) Hypoxic LIMD1 induction decreases expression of HIF target 3	
genes in hypoxia. RNA was extracted from the isogenic cell lines following 24 hours 4	
hypoxic exposure and a panel of HIF-1 downstream targets were quantified by qRT-5	
PCR. The HREmut line had significantly increased HIF-1-driven gene expressions 6	
compared to the HREwt line. (K) Hypoxic LIMD1 induction decreases VEGF 7	
secretion in hypoxia. The isogenic cell lines were incubated in hypoxia for 48 hours 8	
and VEGF secretion was quantified by ELISA, identifying the HREmut line as 9	
secreting a significantly increased VEGF-A protein when compared to the HREwt 10	
line. Unless otherwise stated, data shown is mean ±SEM, n=3, *p<0.05, **p<0.01, 11	
***p<0.001, n.s. = not significant, according to the studentÕs t-test. 12	
 13	
Figure 4: LIMD1 regulates HIF-1α at the post-translational level. (A) The hypoxic 14	
induction of LIMD1 facilitates HIF protein degradation. Western blot analysis of 15	
HREwt and HREmut U2OS lines exposed to hypoxia and the translation inhibitor 16	
cyclohexamide (Cx) treatment for the indicated time-points. HIF-1α protein is 17	
degraded more efficiently in the HREwt line where LIMD1 expression is increased in 18	
hypoxia as detected by immunoblot. (B) HIF-1α rate of decay (ROD) is significantly 19	
slower in HREmut U20S compared to HREwt. Densitometric analysis of HIF-1α 20	
protein, double normalised to β-Actin and 0 minutes Cx treatment in each line, was 21	
used to calculate ROD (Δ relative protein densitometry per minute) of HIF-1α protein 22	
between 0-30 minutes of Cx treatment. (C) The increase in HIF target gene 23	
expression in the HREmut lines is due to HIF protein expression. siRNA targeting HIF-24	
1α and HIF-2α was transfected into the HREwt and HREmut cell lines, and protein 25	
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depletion was confirmed by immunoblot, which resulted in decreased expression of 1	
VEGF mRNA as analysed by qRT-PCR from the simultaneous extraction of RNA 2	
(D). (E) LIMD1 expression does not affect miRNA silencing of HIF-1α and HIF-2α 3	
3ÕUTR in normoxia or hypoxia. The 3ÕUTR of either HIF-1α or HIF-2α was cloned into 4	
the psiCheck2 luciferase vector. These were then transfected into LIMD1 expressing 5	
control (LIMD1+/+) or LIMD1 knockout (LIMD1-/-) HeLa cells and luciferase activity 6	
assayed. Expression of LIMD1 did not affect the stability or silencing of either the 7	
HIF-1α or HIF-2α 3ÕUTR containing reporters. Unless otherwise stated, data shown 8	
is mean ±SEM, n=3, *p<0.05, **p<0.01, ***p<0.001, n.s. = not significant, according 9	
to the studentÕs t-test. 10	
 11	
Figure 5: Increased LIMD1 expression in hypoxia inhibits tumour growth and 12	
vascularisation. (A) Hypoxic LIMD1 induction decreases HIF-1-luciferase activity in 13	
hypoxia. Isogenic HREwt and HREmut A549 cell lines were co-transfected with a 14	
synthetic HIF-1- driven luciferase (pNL-HRE) and pGL3 Firefly normalisation 15	
plasmid, prior to exposure to hypoxia.  Luciferase activity was assayed and 16	
normalised against HRE activity in the HREwt line. (B) Hypoxic LIMD1 induction 17	
decreases endogenous HIF-mediated gene expression in hypoxia. RNA was 18	
extracted from the isogenic cell lines following 24 hours hypoxic exposure and the 19	
expression of a panel of HIF-1 target genes was quantified by qRT-PCR. The 20	
HREmut line had significantly increased HIF-1-driven gene expression compared to 21	
the HREwt line. (C) Hypoxic LIMD1 induction decreases VEGF secretion in hypoxia. 22	
The isogenic cell lines were incubated in hypoxia for 48 hours and VEGF secretion 23	
was quantified by ELISA, identifying the HREmut line as secreting a significantly 24	
increased level of VEGF-A protein when compared to the HREwt line. (D) The 25	
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hypoxic increase in LIMD1 expression decreases 3D tumour growth in vivo. 8-12 1	
week old female SCID beige mice were injected subcutaneously with 5x109 2	
HREwt/mut cells and subsequent xenograft growth measured until the first 3	
measurement exceeded the legal limit of 1.44cm2. HREwt derived xenografts were 4	
smaller in volume compared to the HREmut where LIMD1 expression was 5	
unresponsive to hypoxia. n=25 for each cell line, statistical significance analysed 6	
using the Mann-Whitney test. (E) HREwt derived xenografts have lower blood vessel 7	
density compared to HREmut derived xenografts. Xenografts were snap frozen in 8	
liquid nitrogen, sectioned and stained with endomucin (red) and DAPI (blue) (upper 9	
panels). Lower panels show endomucin staining in white for visual clarity. Scale bar, 10	
100µm. (F) Blood vessels were manually counted throughout the entire section and 11	
xenograft cross sectional area calculated. n=25 for each cell line. (G) HREwt derived 12	
xenografts have lower expression of the blood vessel marker endomucin. RNA was 13	
extracted from snap frozen xenografts and analysed by qRT-PCR. In addition HREwt 14	
xenografts also had lower expression of the HIF driven genes (H) VEGF-A, (I) HK1 15	
and (J) PDK1. *p<0.05. Unless otherwise stated, data shown is mean ±SEM, n=3, 16	
*p<0.05, **p<0.01, ***p<0.001, n.s. = not significant, according to the studentÕs t-test. 17	
 18	
Figure 6: Loss of LIMD1 expression is a poor prognostic indicator in lung 19	
cancer. (A) Representative immunohistochemistry (IHC) staining of cores for LIMD1 20	
that were scored in the 276 patient sample TMA to ascertain relative expression (H-21	
score) of each within the cohort (B). Scale bar 100µm; 20µm on zoom panel. (C) 22	
Kaplan-Meier analysis identifies patients stratified as having high LIMD1 expression 23	
(intense staining) exhibit poorer overall survival compared to low (weak staining).  24	
(D) Copy number alterations of LIMD1 and other validated tumour suppressor genes 25	
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from a lung adenocarcinoma (LUAD) cohort, publically available from TCGA. (E) 1	
Stratification of TCGA LUAD cohort into quartiles based on LIMD1 mRNA expression 2	
(where Q1= lowest expression quartile, Q3= highest expression quartile) 3	
demonstrates worse overall survival for patients within the lowest LIMD1-expressing 4	
quartile (Low Exp) compared to the highest LIMD1-expressing quartile (High Exp). 5	
(F) Correlation analysis of LIMD1 mRNA expression in patients from (D) identified a 6	
significant inverse correlation between LIMD1 and HIF target genes SLC2A1, (G) 7	
GAPDH and (H) IGF2BP2.  (I) Stratification of TCGA LUAD cohort into quartiles 8	
based on SLC2A1, (J) GAPDH and (K) IGF2BP2 demonstrates worse overall 9	
survival for patients within the highest expressing quartile (High Exp) compared to 10	
the highest expressing quartile (High Exp) for each gene.  11	
Figure 7: Proposed model of the HIF-1-LIMD1 negative regulatory feedback 12	
mechanism. HIF-1α is stabilised in hypoxia and heterodimerises with HIF-1β, 13	
forming an active HIF-1 transcription factor complex with CBP/p300. HIF-1 binds to 14	
hypoxic response elements (HRE) within the promoters of genes that are required 15	
for hypoxic survival and adaptation, increasing their gene expression. Classically, 16	
these include genes required for metabolic adaptation and angiogenesis. Here we 17	
identify that the tumour suppressor gene LIMD1 is also a HIF-1 responsive gene, 18	
and in hypoxia its expression is increased at both the mRNA and protein level. This 19	
increased expression facilitates formation of a hypoxic PHD2-LIMD1-VHL 20	
degradation complex, facilitating hypoxic HIF-1α degradation. In turn, this attenuates 21	
the tumourigenic cellular adaption to hypoxia and subsequent tumourigenesis, thus 22	
identifying a new level of complexity of a tumour suppressive mechanism of LIMD1.	23	
	24	
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